0001607854-17-000001.txt : 20170118 0001607854-17-000001.hdr.sgml : 20170118 20170118115549 ACCESSION NUMBER: 0001607854-17-000001 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170118 DATE AS OF CHANGE: 20170118 EFFECTIVENESS DATE: 20170118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lysosomal Therapeutics, Inc. CENTRAL INDEX KEY: 0001607854 IRS NUMBER: 454015802 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-233905 FILM NUMBER: 17532833 BUSINESS ADDRESS: STREET 1: 19 BLACKSTONE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-714-9620 MAIL ADDRESS: STREET 1: 19 BLACKSTONE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 D/A 1 primary_doc.xml X0707 D/A LIVE 0001607854 Lysosomal Therapeutics, Inc. 19 BLACKSTONE STREET CAMBRIDGE MA MASSACHUSETTS 02139 617-714-9620 DELAWARE None None Corporation true Cornelis Been c/o Lysosomal Therapeutics, Inc. 19 Blackstone Street Cambridge MA MASSACHUSETTS 02139 Executive Officer Director Carole Neuchterlein c/o Lysosomal Therapeutics, Inc. 19 Blackstone Street Cambridge MA MASSACHUSETTS 02139 Director Clay Thorp c/o Lysosomal Therapeutics, Inc. 19 Blackstone Street Cambridge MA MASSACHUSETTS 02139 Director Daniel Geffken c/o Lysosomal Therapeutics, Inc. 19 Blackstone Street Cambridge MA MASSACHUSETTS 02139 Executive Officer Robert Carpenter c/o Lysosomal Therapeutics, Inc. 19 Blackstone Street Cambridge MA MASSACHUSETTS 02139 Executive Officer Director Bruce Booth c/o Lysosomal Therapeutics, Inc. 19 Blackstone Street Cambridge MA MASSACHUSETTS 02139 Director Bernard Davitian c/o Lysosomal Therapeutics, Inc. 19 Blackstone Street Cambridge MA MASSACHUSETTS 02139 Director Steven Hall c/o Lysosomal Therapeutics, Inc. 19 Blackstone Street Cambridge MA MASSACHUSETTS 02139 Director Biotechnology Decline to Disclose 06b true 0001607854-15-000001 2015-01-30 false true false 0 26124936 26124936 0 false 9 0 0 0 false Lysosomal Therapeutics, Inc. /s/ Cornelis Been Cornelis Been President & CEO 2017-01-13